# Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma

> **NCT02011113** · PHASE2 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 36 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Pomalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02011113
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2014-09
- **Final completion:** 2015-09
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2016-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02011113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02011113, "Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02011113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*